WEBINAR ALERT: Consensus Recommendations for a Standardized Brain Tumor Imaging Protocol (BTIP) in Clinical Trials
Webinar to Discuss New Consensus Recommendations for a Standardized Brain Tumor Imaging Protocol (BTIP) in Neuro-Oncology Clinical Trials
WHAT: Webinar led by international leaders of Brain Tumor Imaging Standardization Steering Committee will educate neuro-oncology and neuroimaging field on latest recommendations for MRI use in clinical studies
WHEN: Tuesday, September 22, 11:00 AM – 12:00 PM (EST)
WHERE: Register here: http://bit.ly/BTIPwebinar
WHO: Leaders from the international neuro-oncology and neuroimaging field:
- Daniel Barboriak, MD, Duke University Medical Center, Professor of Radiology and Pediatrics, Department of Neuroradiology
- Martin Bendszus, MD, University of Heidelberg (Germany), Chairman, Department of Neuroradiology
- Benjamin Ellingson, PhD, MSc, University of California, Los Angeles, Associate Professor of Radiology, Biomedical Physics, Psychiatry, and Bioengineering; Director, UCLA Brain Tumor Imaging Laboratory; Co-Director, UCLA Center for Computer Vision and Imaging Biomarkers; Department of Radiological Sciences
- Patrick Wen, MD, Brigham and Women’s/Dana-Farber Cancer Institute, Harvard Medical School, Director of the Center for Neuro-Oncology and Division of Cancer Neurology at BWH/Dana-Farber Cancer Institute
WHY: In addressing the issues associated with brain tumor imaging, the development and adoption of a standardized MRI protocol in brain tumor clinical trials will validate and build confidence in the use of quantitative imaging surrogates as endpoints in GBM clinical trials for drugs seeking FDA approval, including but not limited to the ‘Accelerated Approval’ pathway. In addition, it is anticipated that the designation and acceptance of a standardized protocol will incentivize brain tumor treatment development by providing clarity and efficiency, as well as time and cost savings, for clinical trial sponsors to ultimately generate a pipeline of therapeutic candidates. For a full press release on the new consensus recommendations for the BTIP, see here.
About the Jumpstarting Brain Tumor Drug Development Coalition
The Jumpstarting Brain Tumor Drug Development Coalition is made up of four of the leading brain tumor-focused organizations in the United States, encompassing venture philanthropy; patient advocacy; public policy advocacy; research funding and advancement; education; and representing thousands of patients, caregivers, survivors, clinicians, and researchers. The Coalition aims to achieve the most favorable clinical trials process possible for advancing new treatments for brain tumor patients. Learn more.